This collection contains reports by the Assistant Secretary for Planning and Evaluation (ASPE). The ASPE advises the Secretary of the Department of Health and Human Services on policy development in health, disability, human services, data, and science; and provides advice and analysis on economic policy. The ASPE leads special initiatives; coordinates the Department's evaluation, research, and demonstration activities; and manages cross-Department planning activities such as strategic planning, legislative planning, and review of regulations. Integral to this role, the ASPE conducts research and evaluation studies; develops policy analyses; and estimates the cost and benefits of policy alternatives under consideration by the Department or Congress.

Contents

• ASPE Report: Competition in Prescription Drug Markets, 2017-2022
  Sonal Parasrampuria and Stephen Murphy.
  Washington (DC): Office of the Assistant Secretary for Planning and Evaluation (ASPE); December 2023.
• Advancing Research on Intersections of Child Welfare and Medicaid Using Linked Data from the CCOULD Project: Issue Brief
  Brett Greenfield, Emily Madden, and Robin Ghertner.
  Washington (DC): Office of the Assistant Secretary for Planning and Evaluation (ASPE); November 2023.
• Project Update: Child Welfare and Health Infrastructure for Linking and Data Analysis of Resources, Effectiveness, and Needs (CHILDREN) Initiative: Issue Brief
  Brett Greenfield, Laura Chadwick, Emily Madden, and Marissa Abbott.
  Washington (DC): Office of the Assistant Secretary for Planning and Evaluation (ASPE); November 2023.
• Surging the Public Health Workforce: Lessons Learned from the COVID-19 Response at State, Tribal, Local, and Territorial Public Health Agencies: ASPE Report
  Mathematica; Katie Morrison Lee, Alyssa Bosold, Cindy Alvarez, Diane Rittenhouse, Sue Felt-Lisk, Faye Miller, and Chris Palo.
  Washington (DC): Office of the Assistant Secretary for Planning and Evaluation (ASPE); September 2023.
• Understanding Markets for Antimicrobial Drugs: Issue Brief
  Sullivan Casey and Kolbe Allison.
  Washington (DC): Office of the Assistant Secretary for Planning and Evaluation (ASPE); August 2023.
• ASPE Report to Congress: Impact of Drug Shortages on Consumer Costs
  Office of the Assistant Secretary for Planning and Evaluation (ASPE).
  Washington (DC): Office of the Assistant Secretary for Planning and Evaluation (ASPE); May 2023.
• Best Practices for COVID-19 Vaccination and Testing: Environmental Scan Report: ASPE Report
  Mathematica; Eli Michaels, Cindy Alvarez, Katharine Bradley, Alyssa Bosold, Colleen Staatz, Ruth Hsu, and Sheila Hoag.
  Washington (DC): Office of the Assistant Secretary for Planning and Evaluation (ASPE); April 2023.
• FDA User Fees: Examining Changes in Medical Product Development and Economic Benefits: Issue Brief
  Sonal Parasrampuria and Trinidad Beleche.
  Washington (DC): Office of the Assistant Secretary for Planning and Evaluation (ASPE); March 2023.
• Antimicrobial Drugs - Burden of Antimicrobial Resistance: Final Report
  Aylin Sertkaya, J. Daniel McGeeney, Calvin Franz, Clara Berger, Owen Stokes-Cawley, and Natalie Rodman.
  Washington (DC): Office of the Assistant Secretary for Planning and Evaluation (ASPE); December 26, 2022.
• Analysis of Market Challenges for Antimicrobial Drug Development in the United States: Final Report
  Aylin Sertkaya, Ayesha Berlind, J. Daniel McGeeney, Clara Berger, and Owen Stokes-Cawley.
  Washington (DC): Office of the Assistant Secretary for Planning and Evaluation (ASPE); December 23, 2022.
• Antimicrobial Drugs Market Returns Analysis: Final Report
  Aylin Sertkaya and Calvin Franz.
  Washington (DC): Office of the Assistant Secretary for Planning and Evaluation (ASPE); December 16, 2022.
• Linking Child Welfare and Medicaid Data: Lessons Learned from Two States: Child and Caregiver Outcomes Using Linked Data (CCOULD) OPRE & ASPE Report
  Tami L. Mark, Melissa Dolan, Benjamin Allaire, and Christina Bradley.
  Washington (DC): Office of the Assistant Secretary for Planning and Evaluation (ASPE); October 2022.